Intradetrusor onabotulinumtoxinA for overactive bladder

Bibliography

• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012.188(Suppl 6):2455-63. Available from: www.auanet.org http://www.auanet.org/common/pdf/education/clinical-guidance/Overactive-Bladder.pdf [Accessed 30 September 2013]
   Google Scholar
• Supplemental BLA Approval: OnabotulinumA for Neurogenic Bladder. Food and Drug Administration. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/103000s5232ltr.pdf [Accessed 9 October 2013]
   Google Scholar
• Supplement Approval: OnabotulinumA for Non-Neurogenic Bladder. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/103000Orig1s5251ltr.pdf [Accessed 9 October 2013]
   Google Scholar
• Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000;342(9):665
   PubMed Web of Science ®Google Scholar
• Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187(6):2131-9
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-6
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186-93
   PubMed Web of Science ®Google Scholar
• Chapple C, Sievert K-D, Macdiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249-56
   PubMed Web of Science ®Google Scholar
• Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22
   PubMed Web of Science ®Google Scholar
• Flynn MK, Amundsen CL, Perevich M, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009;181:2608-15
   PubMed Web of Science ®Google Scholar
• Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-9
   PubMed Web of Science ®Google Scholar
• Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62:507-14
   PubMed Web of Science ®Google Scholar
• BOTOX [package insert]. Highlights of Prescribing Information, BOTOX Cosmetic [package insert]. Allergan Pharmaceuticals; Irvine, CA; 2013. Available from: http://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf. [Accessed 4 March 2014]
   Google Scholar
• Cruz F. Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn 2014;33(1):31-8
   PubMed Web of Science ®Google Scholar
• Werner M, Schmid DM, Schussler B. Efficacy of botulinum- A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005;192:1735-40
   PubMed Web of Science ®Google Scholar
• Duthie JB, Vincent M, Herbison GP. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011;(12):CD005493
   Google Scholar
• Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53(2):275-87
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22
   PubMed Web of Science ®Google Scholar
• Denys P, Le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012;61:520-9
   PubMed Web of Science ®Google Scholar
• Manecksha RP, Cullen IM, Ahmad S, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 2012;61(5):928-35
   PubMed Web of Science ®Google Scholar
• Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder—to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 2010;184(6):2423-8
   PubMed Web of Science ®Google Scholar
• Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med 2012;367(19):1803-13
   PubMed Web of Science ®Google Scholar
• Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006;175(3 Pt 1):835
   PubMed Web of Science ®Google Scholar
• Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology 2013;81(3):491-7
   PubMed Web of Science ®Google Scholar
• Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010;75(3):552-8
   PubMed Web of Science ®Google Scholar
• Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of OnabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60(4):742-50
   PubMed Web of Science ®Google Scholar
• Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol 2013;189(5):1804-10
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010;58(6):919-26
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-36
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50(6):1306-14
   PubMed Web of Science ®Google Scholar
• Gopal M, Haynes K, Bellamy SL, et al. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008;112(6):1311
   PubMed Web of Science ®Google Scholar
• Kessler TM, Khan S, Panicker J, et al. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009;113(5):1046-51
   PubMed Web of Science ®Google Scholar